Topic:

Device Studies

Latest Headlines

Latest Headlines

Cellnovo partners with TypeZero in major NIH-backed artificial pancreas trial in Type 1 diabetics

Paris-based Cellnovo Group has partnered with TypeZero Technologies to be part of a previously announced clinical trial of an artificial pancreas that's being backed by a $12.8 million grant from the U.S. National Institutes of Health. Cellnovo's connected insulin patch pump will be used in conjunction with TypeZero's inControl AP software and a Dexcom continuous glucose monitor to form the whole of the artificial pancreas system being tested.

Study: Smart contact lens offers continuous monitoring of glaucoma progression

Researchers have found that smart contact lenses that emit patterns of electrical signals can be used to detect the rate of glaucoma. The smart contact lens system, known as Triggerfish, is from Swiss startup Sensimed and is designed as a diagnostic. It offers an automated, continuous recording of ocular dimensional changes when worn over a 24-hour period.

German radiosurgery player Brainlab invests $7M+ in Jan Medical for portable concussion Dx

Munich-based radiotherapy company, Brainlab, has invested a $7.5 million Series C financing into Mountain View, CA-based startup Jan Medical. The cash infusion is earmarked for the completion of ongoing clinical trials and submission of its neurological diagnostic software, Nautilus BrainPulse, to regulators.

UPDATED: U.K.'s NHS launches a series of med tech trials with Google's Verily, IBM, Philips

The United Kingdom's National Health Service sees med tech as crucial to addressing healthcare improvements. It's launched a series of 7 trials with several major technology partners designed to test several means of integrating med tech specifically into at-home care for elderly and chronic disease patients.

U.S. pivotal trial starts for Senseonics glucose monitor implant with data due in June

Upstart Senseonics expects to be the first to introduce a long-term implant to continuously monitor glucose levels in diabetics. It's already under review for a CE mark after disclosing pivotal European data in October. Now, it's detailed the plans for the pivotal U.S. study of its Eversense Continuous Glucose Monitoring System.

Study finds Masimo respiratory monitor more useful in tracking IV patients

Longtime oxygen monitor leader Masimo is touting a study that found its acoustic respiration rate as measured by its Rainbow Acoustic Monitoring is more effective at monitoring dental patients who are under intravenous anesthesia than conventional capnography.

Scripps trial finds digital health devices don't improve healthcare use or outcomes

At the annual AdvaMed convention, Dr. Eric Topol of the Scripps Research Institute laid out his vision of a healthcare future dominated by mobile patient monitors and real-time sensors. Alas, a 160-patient, 6-month randomized controlled trial by Topol and others found little evidence of economic benefit as a result of interventions with mobile devices.

French startup raises $27M from Chinese investor for noninvasive ultrasound glaucoma treatment

Eye Tech Care has nabbed a commitment from China-focused investor Everpine Capital to invest about €24.8 million ($26.9 million) in two rounds. The firm has already invested an initial, undisclosed amount and it's working with the Lyon-based startup to gain a regulatory approval from the China Food and Drug Administration for its noninvasive glaucoma ultrasound treatment, which is already marketed in Europe.

NIH backs smartphone-based artificial pancreas trials with almost $13M

The U.S. National Institutes of Health is financing what's expected to be the largest long-term clinical study for an artificial pancreas to regulate the blood sugar levels in Type 1 diabetics to the tune of $12.7 million. This is the biggest chunk it's yet doled out as part of a program the agency started in 2014 to promote testing of artificial pancreas systems that's already backed at least three other research efforts.

Gelesis drops IPO, raises $31.5M for pivotal U.S. trial of hydrogel weight-loss capsule

Weight loss and glycemic control startup Gelesis had hoped to take advantage of the most recent med tech IPO window. Instead, it's opted to pull a proposed $52 million IPO and go back to the well with VCs. It's raised $31.5 million in a financing round led by new investor Cormorant Asset Management, bringing its total raised to in excess of $90 million.